Home › Non-Small Cell Lung Cancer › Michigan
Non-Small Cell Lung Cancer clinical trials in Michigan
101 studies for Non-Small Cell Lung Cancer are looking for participants at sites in Michigan.
Cities in Michigan
- Detroit44 studies
- Grand Rapids44 studies
- Ann Arbor26 studies
- Farmington Hills13 studies
- Lansing9 studies
- Flint9 studies
- Canton8 studies
- Livonia8 studies
- Waterford8 studies
- Saginaw7 studies
- Dearborn6 studies
- Wyoming6 studies
- Kalamazoo6 studies
- Norton Shores5 studies
- Clinton Township4 studies
- Warren4 studies
- Muskegon4 studies
- Troy3 studies
A Study of ZW251 in Participants With Advanced Solid Tumors
- START Midwest, Grand Rapids
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT07164313Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
- Bronson Battle Creek, Battle Creek
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Grand Rapids
- Bronson Methodist Hospital, Kalamazoo
- and 7 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT07388524Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
- Henry Ford Hospital - Detroit /ID# 271642, Detroit
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT06772623Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Bronson Battle Creek, Battle Creek
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- and 50 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT04267848Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
- START - Midwest, Grand Rapids
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT06784193A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- South Texas Accelerated Research Therapeutics (START), Grand Rapids
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06270706A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- Trinity Health Medical Center - Brighton, Brighton
- and 7 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07293247A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- START Midwest Cancer and Hematology Centers of W Michigan, Grand Rapids
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06465069A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
- Research Site, Detroit
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06996782Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #65, Detroit
- Exelixis Clinical Site #13, Detroit
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT05176483Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- University of Michigan Rogel Cancer Center, Ann Arbor
- Bronson Battle Creek, Battle Creek
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- and 38 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06498635177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- BAMF Health, Grand Rapids
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07189871A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
- Karmanos Cancer Institute, Detroit
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07361497A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
- ALX Center 8, Farmington Hills
- ALX Center 3, Grand Rapids
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07085091Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- Trinity Health Ann Arbor Hospital, Ann Arbor
- Karmanos Cancer Institute, Detroit
- Henry Ford Health, Detroit
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06881784A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
- Research Site, Saginaw
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06868277A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- University of Michigan Health System, Ann Arbor
- Trinity Health St Joseph Mercy Ann Arbor, Ypsilanti
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06667076This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Corewell Health - Butterworth Hospital, Grand Rapids
- Corewell Health - Lemmen Holton Cancer Pavilion, Grand Rapids
- Corewell Health - Research Specimen Processing Area, Grand Rapids
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06758401Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- MyMichigan Medical Center Gratiot, Alma
- MyMichigan Medical Center Alpena, Alpena
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- and 48 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT03191149Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Karmanos Cancer Institute, Detroit
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06890598Pan-tumor MRD Study
- The Cancer & Hematology Centers (CHC), Grand Rapids
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06605404Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Research Site, Dearborn
- Research Site, Farmington Hills
- Research Site, Grand Rapids
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06357533A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
- University of Michigan Health Systems, Ann Arbor
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07140016A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Profound Research LLC - MHP MedOnc Royal Oak - Oakland Medical Group Location, Royal Oak
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06561386A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Local Institution - 0293, Detroit
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06875310A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
- Barbara Ann Karmanos Cancer Center, Detroit
- START Midwest, Grand Rapids
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07488676Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- START Midwest, Grand Rapids
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06128551A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
- University of Michigan Medical School Rogel Cancer Center, Ann Arbor
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT07629960A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Research Site, Detroit
- Research Site, Grand Rapids
- Research Site, Saginaw
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT06692738Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- START Midwest, Grand Rapids
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT05267626A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
- Karmanos Cancer Institute, Detroit
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT06855771Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Clinical Study Site, Ann Arbor
- Clinical Study Site, Detroit
- Clinical Study Sites, Detroit
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT06767514Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
- START Midwest, Grand Rapids
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07349537A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
- BAMF Health, Grand Rapids
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07020117Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT05786924Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Cancer & Hematology Centers of Western Michigan - East /ID# 261826, Grand Rapids
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT06236438ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Cancer & Hematology Centers of Western Michigan, Grand Rapids
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT05059444A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
- University of Michigan, Ann Arbor
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT04302025A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
- START | Midwest, Grand Rapids
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT06914128A Phase 1/1b Study of IAM1363 in HER2 Cancers
- University of Michigan, Ann Arbor
- Henry Ford Cancer Institute, Detroit
- START - Midwest Cancer Research Center, Grand Rapids
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06253871From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.